Summit Therapeutics (SMMT)
Develops Akeso-origin ivonescimab through multinational late-stage oncology trials.
$16.40
vs last close−0.72 (−4.21%)
Something off on this page? Send us feedback.
Next report
Oct 19, 26
in 26 days
EPS estimate
−$0.28
Revenue estimate
$71.4K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$0.08−$0.09−$0.76−$0.31−$0.29−$0.24−$0.28Pending
Estimate−$0.08−$0.09−$0.09−$0.18−$0.10−$0.33−$0.27−$0.28
Surprise+2.2%+3.2%−736.9%−76.4%−182.5%+27.3%−2.0%—
RevenueReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported———————Pending
Estimate———$76.5M$56.8M$54.4K$113.9K$71.4K
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.33 | — | — |
| Sep 2027 | −$0.32 | — | — |
| Jun 2027 | −$0.31 | — | — |
| Mar 2027 | −$0.27 | — | — |
| Dec 2026 | −$0.36 | — | — |
| Oct 2026 | −$0.28 | — | — |
| Jul 2026 | −$0.27 | −$0.28 | −2.0% |
| Apr 2026 | −$0.33 | −$0.24 | +27.3% |
| Feb 2026 | −$0.10 | −$0.29 | −182.5% |
| Oct 2025 | −$0.18 | −$0.31 | −76.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Dec 2019 | |||
| Jul 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Apr 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| May 2016 | |||
| Jun 2016 | |||
| Dec 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.33 | — | — | $25.5M | — | — | — |
| Sep 2027 | −$0.32 | — | — | $18.0M | — | — | — |
| Jun 2027 | −$0.31 | — | — | $17.4M | — | — | — |
| Mar 2027 | −$0.27 | — | — | $12.4M | — | — | — |
| Dec 2026 | −$0.36 | — | — | $4.0M | — | — | — |
| Oct 19, 2026 | −$0.28 | — | — | $71.4K | — | — | — |
| Jul 23, 2026 | −$0.27 | −$0.28 | −2.0% | $113.9K | — | — | −8.8% |
| Apr 30, 2026 | −$0.33 | −$0.24 | +27.3% | $54.4K | — | — | +3.0% |
| Feb 23, 2026 | −$0.10 | −$0.29 | −182.5% | $56.8M | — | — | +0.2% |
| Oct 20, 2025 | −$0.18 | −$0.31 | −76.4% | $76.5M | — | — | −4.5% |
| Aug 11, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 24, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 1, 2024 | |||||||
| Feb 20, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 9, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 11, 2022 | |||||||
| Mar 17, 2022 | |||||||
| Nov 15, 2021 | |||||||
| Aug 11, 2021 | |||||||
| May 17, 2021 | |||||||
| Mar 17, 2021 | |||||||
| Nov 16, 2020 | |||||||
| Sep 29, 2020 | |||||||
| Jun 3, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Dec 17, 2019 | |||||||
| Jul 31, 2019 | |||||||
| Jun 12, 2019 | |||||||
| Mar 27, 2019 | |||||||
| Dec 11, 2018 | |||||||
| Sep 20, 2018 | |||||||
| Jun 5, 2018 | |||||||
| Apr 13, 2018 | |||||||
| Dec 6, 2017 | |||||||
| Aug 31, 2017 | |||||||
| Jun 14, 2017 | |||||||
| Mar 29, 2017 | |||||||
| Dec 15, 2016 | |||||||
| Sep 8, 2016 | |||||||
| May 10, 2016 | |||||||
| Jun 2, 2016 | |||||||
| Dec 17, 2015 | |||||||
| Aug 27, 2015 |